Nachrichten zur Eli Lilly & Co. Aktie

Will Policy Shifts Accelerate Demand for Eli Lillys GLP-1 Drugs?

LLY is likely to see stronger demand for its GLP-1 drugs as Medicare expands coverage and the company prepares to…

Former Eli Lilly executive joins Hims & Hers to lead communications during growth phase

Beiser joins the telehealth company from Eli Lilly as it expands internationally and builds out its Phoenix operations.…

Should You Chase the Rally in Hims & Hers Stock Today?

Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug…

Eli Lilly: The Weight-Loss Craze Isnt Over

…

Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks

Compounded weight-loss drugs that contain vitamin B12 and the main ingredient in Eli Lillys ?Zepbound could present health risks to…

Eli Lilly to invest $3 billion in China, seeks approval for new GLP-1 drug

Eli Lilly to invest $3 billion in China, seeks approval for new GLP-1 drug…

Hims And Hers Taps Veteran Communicator To Shape GLP 1 Growth Story

Hims & Hers Health (NYSE:HIMS) has appointed Kathryn Beiser as Chief Communications Officer.Beiser brings senior communications experience from Eli Lilly,…

Hims & Hers Names Kathryn Beiser as Chief Communications Officer

The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world’s leading consumer health…

Hims & Hers Names Kathryn Beiser as Chief Communications Officer

The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world’s leading consumer health…

Eli Lilly (LLY) Laps the Stock Market: Heres Why

In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a +1.82% move from the…

Should You Buy Eli Lilly Stock Now or Wait for More of a Pullback?

Eli Lillys stock is a bit expensive, even with a bit of a decline this year.…

Zacks Market Edge Highlights: Caterpillar, Eli Lilly and Comfort Systems

Caterpillar, Eli Lilly and Comfort Systems have been highlighted in this Market Edge article.…

1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid

Eli Lilly may be the GLP-1 leader, but its valuation is stretched.…

Where Will Eli Lilly Stock Be in 10 Years?

Eli Lilly is at the head of the pharma pack today, but in a decade, the situation could look very…

Market turmoil is hitting most traditional safe havens. UBS says this is the place to hide

Pharmaceutical stocks like Eli Lilly and Merck are good places to help investors ride out a recent rise in geopolitical…

Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.

Employers can use Lillys platform to connect with different third-party program administrators that help manage obesity treatment benefits and costs.…

Drugmaker Aspen targets Mounjaro approval in sub-Saharan Africa this year

Aspen Pharmacare aims to secure sub?Saharan African approval for Eli Lillys blockbuster weight?loss drug Mounjaro as early as this year,…

Rigel Pharma (RIGL) Earnings Call Transcript

Image source: The Motley Fool.DateTuesday, March 3, 2026 at 4:30 p.m. ETCall participantsChief Executive Officer — Raul R. RodriguezChief Commercial…

Up Over 400% in 5 Years, Is It Too Late to Invest in Eli Lilly Stock?

Eli Lilly has been a growth beast in recent years, but its valuation has gotten fairly high along the way.…

Up Over 400% in 5 Years, Is It Too Late to Invest in Eli Lilly Stock?

Key PointsEli Lillys stock has skyrocketed in value due to the success of its popular GLP-1 products.…

Should You Forget Eli Lilly and Buy This Magnificent High-Yield Dividend Stock Instead?

Eli Lilly is making headlines in the pharmaceutical sector, but its a very expensive stock.…

OPKO Health (OPK) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.DateFeb. 26, 2026Call participantsChairman and Chief Executive Officer — Phillip FrostVice Chairman and President — Elias…

Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Heres What You Need to Know.

Eli Lilly has seen revenue and earnings soar in recent years.…

Direct-to-consumer sales for obesity drugs are about to boom. JPMorgan sees Eli Lilly as big winner

Thanks to its “best-in-class” status, the bank believes the company will be the winner from a growing GLP-1 patient base.…

Eli Lilly acquires Orna Therapeutics for $2.4B to disrupt CAR-T market

CAR-T therapies have changed the oncology space, but their cost and complexity have confined these treatments to specialized cancer centers,…

Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound

The failure of its next-generation obesity drug to match Eli Lillys blockbuster has blown a hole in Novos post-Ozempic strategy,…

Novos stumbles burnish Lillys widening lead in weight-loss drugs

With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed was…

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen

Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.…

VIEW Novos CagriSema setback may shift investor focus to M&A strategy, analysts say

Novo Nordisks next-generation weight-loss drug CagriSema was less effective than Eli Lillys Zepbound in a head-to-head trial, a fresh blow…

Jim Cramers top 10 things to watch in the stock market Monday

President Trump is raising his threatened global tariff to 15%, and Eli Lilly triumphs over obesity rival Novo Nordisk once…

Lilly to launch multi-dose weight-loss drug device in US

Eli Lilly said on Monday it received the U.S. Food and Drug Administrations approval to launch a four-dose KwikPen for…

Novo Nordisk slump wipes out last Wegovy-era gains after trial setback

Novo Nordisk shares fell more than 15% on Monday, wiping away the last gains Wegovys launch had brought, after the…

Novo Nordisks obesity drug falls short against Eli Lillys in Copenhagen trial

Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed…

Novo Nordisk Stock Investors Just Got Great News From Eli Lilly

But its good news for Eli Lilly, too.…

Barclays initiates Eli Lilly stock coverage with overweight rating By Investing.com

Barclays initiates Eli Lilly stock coverage with overweight rating…

Prediction: Eli Lilly Stock Could Surge 45% This Year

Eli Lilly just delivered explosive growth, and analysts see up to 45% upside, but is this pharma giant still a…

Analysis-Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders

NEW YORK, Feb 19 (Reuters) - Online telehealth company Hims & Hers Health, seeking growth drivers as its original sexual-health…

CSL signs licensing deal with Eli Lilly for clazakizumab By Reuters

CSL signs licensing deal with Eli Lilly for clazakizumab…

Vulcan Materials (VMC) Q4 2025 Earnings Transcript

Image source: The Motley Fool.DateTuesday, Feb. 17, 2026, at 10 a.m. ETCall ParticipantsChief Executive Officer — Ronnie PruittSenior Vice President…

CSL signs licensing deal with Eli Lilly for clazakizumab to treat kidney disease

Australias CSL said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co , granting…

Lilly targets India as global export hub amid booming Mounjaro sales, executive says

Mounjaro-maker Eli Lilly wants to turn India into a hub for its global supply chain, a senior executive at the…

JPMorgan builds $2.93 billion stake in health care stock

JPMorgan Chase just planted a massive $2.93 billion flag in perhaps one of the hottest corners of the market. The…

Eli Lilly Just Delivered Great News for Investors -- and It Goes Beyond Weight-Loss Drugs

Eli Lilly isnt a one-trick pony.…

Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision

Eli Lilly had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug, a filing showed on Thursday,…

Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Heres What Investors Need to Know.

Both companies are betting on interest in weight loss pills.…

Top Analyst Reports for Eli Lilly, Marriott & Fortinet

Eli Lillys Q4 beat and soaring GLP-1 demand lead top analyst picks, alongside fresh insights on Marriott and Fortinets latest…

3 Reasons to Buy Eli Lilly Stock

The healthcare leader looks increasingly unstoppable.…

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Could these two companies be biotech giants in the making?…

Eli Lillys 2025 Surge Sets the Stage for Another Big Year in 2026

LLY posts 45% revenue growth to $65.2B in 2025 as GLP-1 drugs power results, and guides $80-$83B in sales with…